Coadministration of gatifloxacin and multivitamin preparation containing minerals: Potential treatment failure in an elderly patient

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 150-152

  Mallet, Louise ^a,b   Huang, Allen ^b,c,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Division of Geriatric Medicine   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Gatifloxacin; Multivitamin preparation containing minerals; Treatment failure

Indexed keywords

ALUMINUM; CALCIUM CARBONATE; GATIFLOXACIN; IRON; MAGNESIUM; MULTIVITAMIN; SUCRALFATE; ZINC;

AGED; ARTICLE; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL FEATURE; COUGHING; DRUG BIOAVAILABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HOSPITAL INFECTION; HUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; METALS; MINERALS; TREATMENT FAILURE; VITAMINS;

EID: 11144246704     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E392     Document Type: Article

References (16)

1. Perry CM, Ormrod D, Hurst M, Onrust SV. Gatifloxacin - a review of its use in the management of bacterial infections. Drugs 2002;62:169-207.
2. Grasela DM. Clinical pharmacology of gatifloxacin: a new fluoroquinolone. Clin Infect Dis 2003;31(suppl 2):S51-8.
3. Fish DN. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001;21:35-59.
4. Cockroft DW, Gault WH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
5. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21(10 pt. 2):253S-72S.
6. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002;62:1481-502.
7. Nix DE, Watson WA, Lener ME, Frost RW, Krol G, Goldstein H, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-5.
8. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841-4.
9. Van Slooten AD, Nix DE, Wilton JH, Love JH, Spivey JM, Goldstein HR. Combined use of ciprofloxacin and sucralfate. DICP 1991;25:578-82.
10. Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman D. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 1990;34:432-5.
11. Spivey JM, Cummings DM, Pierson NR. Failure of prostates treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy 1996;16:314-6.
12. Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum (letter). Ann Intern Med 1988;109:168-9.
13. Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999;43: 1067-71.
14. Product monograph. Tequin (gatifloxacin) tablets and injection. Montreal: Bristol-Myers Squibb Canada, 2002.
15. Bowes J, Graffunder EM, Lomaestro B, Venezia RA. Concomitant administration of drugs known to decrease the systemic availability of gatifloxacin. Pharmacotherapy 2002;22:800-1.
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.